FDA backs Rocket Pharmaceuticals' Danon disease trial path
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that the U.S. Food and Drug Administration has confirmed key elements of the company's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

